Immunogenicity and protective efficacy of a psoralen-inactivated dengue-1 virus vaccine candidate in Aotus nancymaae monkeys

Vaccine

Volumn 29, Issue 15, 2011, Pages 2691-2696

  Maves, Ryan C ^a   Oré, Roger M Castillo ^a   Porter, Kevin R ^b   Kochel, Tadeusz J ^a  

^a California   (Peru)

^b NAVAL MEDICAL RESEARCH CENTER   (United States)

Author keywords

Dengue 1 vaccine; Inactivated dengue vaccine; Psoralen

Indexed keywords

ALUMINUM HYDROXIDE; DENGUE VACCINE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; NEUTRALIZING ANTIBODY; PSORALEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DETECTION; AOTUS; ARTICLE; CONTROLLED STUDY; CROSS LINKING; DENGUE; DENGUE VIRUS 1; DRUG EFFICACY; IMMUNOGENICITY; NONHUMAN; PHOTOREACTIVITY; PREGNANCY; PRIORITY JOURNAL; ULTRAVIOLET A RADIATION; VACCINATION; VIREMIA; VIRUS INACTIVATION; VIRUS ISOLATION;

ADJUVANTS, IMMUNOLOGIC; ALUM COMPOUNDS; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; AOTIDAE; DENGUE; DENGUE VACCINES; DENGUE VIRUS; DISINFECTANTS; FICUSIN; IMMUNIZATION, SECONDARY; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; TIME FACTORS; VACCINATION; VIREMIA; VIRUS INACTIVATION;

EID: 79952242721     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.01.077     Document Type: Article

References (31)

1. Halstead S.B. Dengue Lancet 2007, 370:1644-1652.
2. Green S., Rothman A. Immunopathological mechanisms in dengue and dengue hemorrhagic fever. Curr Opin Infect Dis 2006, 19:429-436.
3. Wills B.A., Nguyen M.D., Ha T.L., Dong T.H., Tran T.N., Le T.T., et al. Comparison of three fluid solutions for resuscitation in dengue shock syndrome. N Engl J Med 2005, 353:877-889.
4. Panpanich R., Sornchai P., Kanjanaratanakorn K. Corticosteroids for treating dengue shock syndrome. Cochrane Database Syst Rev 2006, 3:CD003488.
5. Dimaano E.M., Saito M., Honda S., Miranda E.A., Alonzo M.T., Valerio M.D., et al. Lack of efficacy of high-dose intravenous immunoglobulin treatment of severe thrombocytopenia in patients with secondary dengue virus infection. Am J Trop Med Hyg 2007, 77:1135-1138.
6. Halstead S.B. Neutralization and antibody-dependent enhancement of dengue viruses. Adv Virus Res 2003, 60:421-467.
7. Groene W.S., Shaw R.D. Psoralen preparation of antigenically intact noninfectious rotavirus particles. J Virol Methods 1992, 38:93-102.
8. Lin L., Hanson C.V., Alter H.J., Jauvin V., Bernard K.A., Murthy K.K., et al. Inactivation of viruses in platelet concentrates by photochemical treatment with amotosalen and long-wavelength ultraviolet light. Transfusion 2005, 45:580-590.
9. Lin L., Dikeman R., Molini B., Lukehart S.A., Lane R., Dupuis K., et al. Photochemical treatment of platelet concentrates with amotosalen and long-wavelength ultraviolet light inactivates a broad spectrum of pathogenic bacteria. Transfusion 2004, 44:1496-1504.
10. Allain J.P., Hsu J., Pranmeth M., Hanson D., Stassinopoulos A., Fischetti L., et al. Quantification of viral inactivation by photochemical treatment with amotosalen and UV A light, using a novel polymerase chain reaction inhibition method with preamplification. J Infect Dis 2006, 194:1737-1744.
11. Berg M., Ros A.M. Treatment of psoriasis with psoralens and ultraviolet A. A double-blind comparison of 8-methoxypsoralen and 5-methoxypsoralen. Photodermatol Photoimmunol Photomed 1994, 10:217-220.
12. Maves R.C., Castillo Ore R.M., Porter K.R., Kochel T.J. Immunogenicity of a psoralen-inactivated dengue virus type 1 vaccine candidate in mice. Clin Vaccine Immunol 2010, 17:304-306.
13. Morens D.M., Halstead S.B., Repik P.M., Putvatana R., Raybourne N. Simplified plaque reduction neutralization assay for dengue viruses by semimicro methods in BHK-21 cells: comparison of the BHK suspension test with standard plaque reduction neutralization. J Clin Microbiol 1985, 22:250-254.
14. Roback J.D., Hossain M.S., Lezhava L., Gorechlad J.W., Alexander S.A., Jaye D.L., Allogeneic T, et al. cells treated with amotosalen prevent lethal cytomegalovirus disease without producing graft-versus-host disease following bone marrow transplantation. J Immunol 2003, 171:6023-6031.
15. Nataraj A.J., Wolf P., Cerroni L., Ananthaswamy H.N. p53 mutation in squamous cell carcinomas from psoriasis patients treated with psoralen+UVA (PUVA). J Invest Dermatol 1997, 109:238-243.
16. Rassner G., Steinert M., Bercher M., Rodermund O.E., Henning D., Mey T., et al. Chronic systemic toxicity of oral photochemotherapy using 8-methoxypsoralen and UVA. Hautarzt 1987, 38:10-17.
17. Maier H., Schemper M., Ortel B., Binder M., Tanew A., Hönigsmann H. Skin tumors in photochemotherapy for psoriasis: a single-center follow-up of 496 patients. Dermatology 1996, 193:185-191.
18. Hearst J.E. Psoralen photochemistry and nucleic acid structure. J Invest Dermatol 1981, 77:39-44.
19. Singh Y., Sawyer L.S., Pinkoski L.S., Dupuis K.W., Hsu J.C., Lin L., et al. Photochemical treatment of plasma with amotosalen and long-wavelength ultraviolet light inactivates pathogens while retaining coagulation function. Transfusion 2006, 46:1168-1177.
20. Brown F. An overview of the inactivation of FMDV and the implications when residual virus is present in vaccines. Dev Biol Stand 1991, 75:37-41.
21. Brown F. Review of accidents caused by incomplete inactivation of viruses. Dev Biol Stand 1993, 81:103-107.
22. Moghaddam A., Olszewska W., Wang B., Tregoning J.S., Helson R., Sattentau Q.J., et al. A potential molecular mechanism for hypersensitivity caused by formalin-inactivated vaccines. Nat Med 2006, 12:905-907.
23. Mongkolsapaya J., Duangchinda T., Dejnirattisai W., Vasanawathana S., Avirutnan P., Jairungsri A., et al. T cell responses in dengue hemorrhagic fever: are cross-reactive T cells suboptimal?. J Immunol 2006, 176:3821-3829.
24. Kyle J.L., Balsitis S.J., Zhang L., Beatty P.R., Harris E. Antibodies play a greater role than immune cells in heterologous protection against secondary dengue virus infection in a mouse model. Virology 2008, 380:296-303.
25. Kliks S. Antibody-enhanced infection of monocytes as the pathogenetic mechanism for severe dengue illness. AIDS Res Hum Retroviruses 1990, 6:993-998.
26. Boonnak K., Slike B.M., Burgess T.H., Mason R.M., Wu S.J., Sun P., et al. Role of dendritic cells in antibody-dependent enhancement of dengue virus infection. J Virol 2008, 82:3939-3951.
27. Dong T., Moran E., Vinh Chau N., Simmons C., Luhn K., Peng Y., et al. High pro-inflammatory cytokine secretion and loss of high avidity cross-reactive cytotoxic T-cells during the course of secondary dengue virus infection. PLoS One 2007, 2:e1192.
28. Simmons C.P., Dong T., Chau N.V., Dung N.T., Chau T.N., Thao le T.T., et al. Early T-cell responses to dengue virus epitopes in Vietnamese adults with secondary dengue virus infections. J Virol 2005, 79:5665-5675.
29. Kliks S.C., Nimmanitya S., Nisalak A., Burke D.S. Evidence that maternal dengue antibodies are important in the development of dengue hemorrhagic fever in infants. Am J Trop Med Hyg 1988, 38:411-419.
30. Kochel T.J., Raviprakash K., Hayes C.G., Watts D.M., Russell K.L., Gozalo A.S., et al. A dengue virus serotype-1 DNA vaccine induces virus neutralizing antibodies and provides protection from viral challenge in Aotus monkeys. Vaccine 2000, 18:3166-3173.
31. Blair P.J., Kochel T.J., Raviprakash K., Guevara C., Salazar M., Wu S.J., et al. Evaluation of immunity and protective efficacy of a dengue-3 pre-membrane and envelope DNA vaccine in Aotus nancymae monkeys. Vaccine 2006, 24:1427-1432.